Italian antitrust authorities are suspecting drug giants Novartis and Roche of a cartel and have launched an investigation into the matter, according to reports. The Italian Competition Authority is looking into whether the companies colluded to keep a drug off the shelves to leave space for a more expensive drug. Reports say the companies worked to keep Avastin, a drug to tread wet age related macular degeneration, off shelves to promote Lucentis, a more expensive but approved drug. Two complaints over the matter were filed to authorities by a private healthcare association and the Italian Opthalmological Society. The two companies in question are based in Switzerland.
Featured News
PlayStation Antitrust Cases Put Closed Console Stores Under Scrutiny
Aug 8, 2026 by
CPI
Antitrust Challenge to GLP-1 Distribution Deals Falls Short in Federal Court
Aug 8, 2026 by
CPI
Republican Senators Introduce Bill to Repeal California Vehicle Emissions Waivers
Aug 6, 2026 by
CPI
Mexican Unions Split Over Antitrust Risks in Volaris-Viva Merger
Aug 6, 2026 by
CPI
Nuclear Power Companies Win Early Dismissal of Worker Wage-Fixing Suit
Aug 6, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes